With IPO Off The Table, Argos Takes $25 Million From VCs
This article was originally published in The Pink Sheet Daily
Executive Summary
The cancer immunotherapy developer withdrew its IPO registration last month, turning instead to insider investors as it prepares for a pivotal Phase III trial on a dendritic cell treatment.
You may also be interested in...
Korea’s Green Gross, Russia’s Pharmstandard Lead $42.5M Argos Financing; Take Local Rights
The personalized immunotherapy developer partnered with Korea’s Green Cross and Russia’s Pharmstandard but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights
The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
Disappointing Provenge Sales Stir Doubts About Demand
Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.